- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-11-16
DOI
10.3389/fphar.2020.580251
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
- (2020) Xi Jin et al. Molecular Cancer
- Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
- (2020) Anwesha Dey et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-proliferative and anti-migratory effects of a novel YAP-TEAD interaction inhibitor identified using in silico molecular docking
- (2019) Sarah Smith et al. JOURNAL OF MEDICINAL CHEMISTRY
- MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
- (2019) Liam Cornell et al. Cell Reports
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).
- (2019) Andreas Schneeweiss et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Zefei Jiang et al. LANCET ONCOLOGY
- CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival
- (2019) Laia Martínez-Carreres et al. CANCER RESEARCH
- LBA8_PRKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- (2019) P Schmid et al. ANNALS OF ONCOLOGY
- LBA25MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2- advanced breast cancer (ABC)
- (2019) Z Jiang et al. ANNALS OF ONCOLOGY
- LBA23MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
- (2019) S M Tolaney et al. ANNALS OF ONCOLOGY
- CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?
- (2019) Meenakshi Anurag et al. CLINICAL CANCER RESEARCH
- PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
- (2019) Carlotta Costa et al. Cancer Discovery
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL
- (2018) Xuehai Bian et al. BIOCHEMICAL PHARMACOLOGY
- Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents
- (2018) Solomon Tadesse et al. BRITISH JOURNAL OF PHARMACOLOGY
- Abstract P5-21-15: The synergistic antitumor activity of entinostat (MS-275) in combination with palbociclib (PD 0332991) in estrogen receptor-positive and triple-negative breast cancer
- (2018) J Lee et al. CANCER RESEARCH
- Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers
- (2018) Meenakshi Anurag et al. CLINICAL CANCER RESEARCH
- A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy
- (2018) Lei Yin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer
- (2018) Takashi Takeshita et al. Molecular Cancer
- Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
- (2018) Chrysiis Michaloglou et al. MOLECULAR CANCER THERAPEUTICS
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
- (2018) Neil Portman et al. ENDOCRINE-RELATED CANCER
- Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.
- (2018) Marleen Kok et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
- (2018) Kamal Pandey et al. INTERNATIONAL JOURNAL OF CANCER
- Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors
- (2018) Zhifen Cui et al. Nature Communications
- Targeting CDK4/6 pathways and beyond in breast cancer
- (2018) Domen Ribnikar et al. BREAST
- Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
- (2017) Sourav Kalra et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
- (2017) Paolo Pronzato Future Oncology
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment
- (2017) Chunai Gong et al. JOURNAL OF CONTROLLED RELEASE
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
- (2017) Nicholas C Turner et al. LANCET
- A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
- (2017) Shumei Song et al. MOLECULAR CANCER THERAPEUTICS
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
- (2017) Julia A. Elvin et al. ONCOLOGIST
- Hippo pathway mediates resistance to cytotoxic drugs
- (2017) Taranjit S. Gujral et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
- (2017) Smruthi Vijayaraghavan et al. Nature Communications
- Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
- (2017) Svasti Haricharan et al. Cancer Discovery
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Targeting FGFR with BGJ398 in Breast Cancer: Effect on Tumor Growth and Metastasis
- (2017) Ana Sahores et al. CURRENT CANCER DRUG TARGETS
- Cytoplasmic Cyclin E and Phospho–Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer
- (2016) Cansu Karakas et al. AMERICAN JOURNAL OF PATHOLOGY
- The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair
- (2016) Diana H. Liang et al. CANCER LETTERS
- ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP
- (2016) Taru Muranen et al. CANCER RESEARCH
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
- (2016) Kelly K. Hunt et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
- (2016) Julien Bollard et al. GUT
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
- (2016) Luca Malorni et al. Oncotarget
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models
- (2015) Xiao Yu Wu et al. Oncotarget
- Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS
- (2015) Barbie Taylor-Harding et al. Oncotarget
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Hippo pathway in mammary gland development and breast cancer
- (2014) P. Shi et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- (2014) Sadhna R. Vora et al. CANCER CELL
- Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer
- (2014) S. Chittaranjan et al. CLINICAL CANCER RESEARCH
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Tongshu Capsule Down-Regulates the Expression of Estrogen Receptor α and Suppresses Human Breast Cancer Cell Proliferation
- (2014) Chengzhi Du et al. PLoS One
- European cancer mortality predictions for the year 2013
- (2013) M. Malvezzi et al. ANNALS OF ONCOLOGY
- YAP/TEAD-Mediated Transcription Controls Cellular Senescence
- (2013) Q. Xie et al. CANCER RESEARCH
- Luminal breast cancer: from biology to treatment
- (2013) Michail Ignatiadis et al. Nature Reviews Clinical Oncology
- The Requirement for Cyclin D Function in Tumor Maintenance
- (2012) Yoon Jong Choi et al. CANCER CELL
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP
- (2012) Y. Liu-Chittenden et al. GENES & DEVELOPMENT
- Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis
- (2012) Michail Ignatiadis et al. JOURNAL OF CLINICAL ONCOLOGY
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- The meaning of p16ink4aexpression in tumors
- (2011) Agnieszka K. Witkiewicz et al. CELL CYCLE
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
- (2010) N. Turner et al. CANCER RESEARCH
- Autophagy: cellular and molecular mechanisms
- (2010) Danielle Glick et al. JOURNAL OF PATHOLOGY
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc
- (2009) C. E. Caldon et al. MOLECULAR AND CELLULAR BIOLOGY
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- Gene-Expression Signatures in Breast Cancer
- (2009) Christos Sotiriou et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started